🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. Lintuzumab-Ac225

    Actinium Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 mab active

    2 trials

  2. Linvoseltamab, Diphenhydramine Hydrochloride 25 mg Tablets, RoActemra 20 mg/mL concentrate for solution for infusion, Dexamethasone 4 mg tablets, Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Paracetamol 500 mg Film-Coated Tablets

    Lacuna Pharma Pty Ltd

    High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-High-Risk Smoldering Multiple Myeloma

    phase 2 small molecule active

    1 trial

  3. Linvoseltamab, Linvoseltamab, RoActemra 20 mg/mL concentrate for solution for infusion, Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Diphenhydramine Hydrochloride 25 mg Tablets, Paracetamol 500mg Tablets, REGN88, Dexamethasone 2mg Tablets

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Systemic Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  4. Liposomal doxorubicin hydrochloride

    Teva Pharma GmbH

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  5. Liposome-encapsulated Daunorubicin-Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

    phase 2 small molecule active

    1 trial

  6. Liposome-encapsulated Daunorubicin-Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 2 small molecule active

    2 trials

  7. Liposome-encapsulated Daunorubicin-Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Essential Thrombocythemia

    phase 2 small molecule terminated

    1 trial

  8. Lotilaner Gel, 2.0%

    Tarsus Pharmaceuticals

    Papulopustular Rosacea

    phase 2 small molecule completed

    1 trial

  9. Low Dose TP-05

    Tarsus Pharmaceuticals

    Healthy Volunteer

    phase 2 small molecule completed

    1 trial

  10. Low dose of MRM-3379

    Mirum Pharmaceuticals International B.V.

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial

  11. Luminity 150 microlitres/ml gas and solvent for dispersion for injection/infusion, TEMOZOLOMIDE , LOMUSTINE

    Pari Pharma GmbH

    Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection, and for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)

    phase 2 small molecule active

    1 trial

  12. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Advanced Soft-tissue Sarcoma

    phase 2 small molecule active

    1 trial

  13. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  14. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Small Cell Lung Cancer ( SCLC )

    phase 2 small molecule active

    1 trial

  15. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Extensive-stage Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  17. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Refractory Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  18. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Locally Advanced Soft Tissue Sarcoma

    phase 2 small molecule terminated

    1 trial

  19. Lurbinectedin 4 MG Injection [Zepzelca]

    Jazz Pharmaceuticals Ireland Limited

    Gastrointestinal Malignancies

    phase 2 small molecule completed

    1 trial

  20. Lutathera 370 MBq/mL solution for infusion, ATEZOLIZUMAB, Tevimbra 100 mg concentrate for solution for infusion, CARBOPLATIN, LysaKare 25 g/25 g solution for infusion, NETSPOT, ETOPOSIDE

    Novartis Pharmaceuticals

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  21. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Lung Cancer

    phase 2 small molecule terminated

    1 trial

  22. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  23. Luxdegalutamide, DZR123, -, -, DOCETAXEL, CABAZITAXEL, ABIRATERONE, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    Metastatic castrate resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  24. Luxdegalutamide, GOZETOTIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources